NASDAQ: JSPRJasper Therapeutics Inc Stock
$23.97+1.16 (+5.09%)
Updated Dec 2, 2024
JSPR Price
$23.97
Fair Value Price
$8.06
Market Cap
$359.58M
52 Week Low
$4.00
52 Week High
$31.01
P/E
-5.08x
P/B
4.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$63.53M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$58M
Beta
0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
JSPR Overview
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JSPR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
C
Momentum
D
Sentiment
D
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
JSPR
Ranked#303 of 343
Ranked#303 of 343
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.05 | A | |
| $7.56 | A | |
| $3.20 | A |
Be the first to know about important JSPR news, forecast changes, insider trades & much more!
JSPR News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JSPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JSPR ($23.97) is overvalued by 197.53% relative to our estimate of its Fair Value price of $8.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
JSPR ($23.97) is not significantly undervalued (197.53%) relative to our estimate of its Fair Value price of $8.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
JSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more JSPR due diligence checks available for Premium users.
Valuation
JSPR fair value
Fair Value of JSPR stock based on Discounted Cash Flow (DCF)
Price
$23.97
Fair Value
$8.06
Overvalued by
197.53%
JSPR ($23.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
JSPR ($23.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
JSPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
JSPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.08x
Industry
-106.56x
Market
28.28x
JSPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.3x
Industry
5.64x
JSPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JSPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.6M
Profit Margin
0%
JSPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$99.4M
Liabilities
$15.7M
Debt to equity
0.19
JSPR's short-term assets ($94.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JSPR's short-term assets ($94.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JSPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JSPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.1M
Investing
-$274.0k
Financing
$9.0k
JSPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
JSPR vs Biotech Stocks
Jasper Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.